BioNetwork West 2016 (past event)
October 05 - 07, 2016
1.888.482.6012
Innovative Dealmaking
06:30 - 07:45 Sunrise Jog
07:45 - 08:45 Registration And Networking Breakfast
08:45 - 08:50 Welcoming Remarks
08:50 - 09:00 Chairperson’s Opening Address
09:00 - 09:15 Biotech Spotlight | Resverlogix Corp.
09:15 - 09:30 Biotech Spotlight | Redhill Biopharm LTD.
General Session
09:30 - 10:10 Panel Discussion | The Evolution of Risk Sharing Models in Today’s Market
Moderator:
Scott E. Goedeke President Viscadia
Speakers:
Stuart Mackey Global Head of Business Development Daiichi Sankyo
Christoph Pittius Vice President, Head of Transactions AstraZeneca
Peter Ginsberg AVP, Business Development United Therapeutics Corporation
Patrick Johnson Vice President of Business Development Allergan, Inc.
Rachna Khosla Executive Director, Business Development Amgen
Scott E. Goedeke President Viscadia
Speakers:
Stuart Mackey Global Head of Business Development Daiichi Sankyo
Christoph Pittius Vice President, Head of Transactions AstraZeneca
Peter Ginsberg AVP, Business Development United Therapeutics Corporation
Patrick Johnson Vice President of Business Development Allergan, Inc.
Rachna Khosla Executive Director, Business Development Amgen
• Overview of the latest variations on risk sharing
• How are up front payments being minimized?
• What are the different investment vehicles being used?
• How are up front payments being minimized?
• What are the different investment vehicles being used?
1:1 Partnering Meetings
09:30 - 10:10 Opening Of 1:1 Partnering MeetingsGeneral Session
10:10 - 10:50 Networking And Refreshment Break1:1 Partnering Meetings
10:10 - 10:50 Opening Of 1:1 Partnering MeetingsGeneral Session
10:50 - 11:30 Panel Discussion | From Sourcing to Alliance Management, The Ins and Outs of Hybrid Deals
The industry continues to evolve toward evermore complex transactions for the development and commercialization of products. With the increasing complexity of deal structure and collaboration objectives, effective alliance management requires new tools and approaches.
• Overview of emerging practices for deals that rely heavily on partnerships
• Establishing governance and strategies to optimize the prospects for success
• Working toward alignment internally and externally on global deals
• Overview of emerging practices for deals that rely heavily on partnerships
• Establishing governance and strategies to optimize the prospects for success
• Working toward alignment internally and externally on global deals
1:1 Partnering Meetings
10:50 - 11:30 Opening Of 1:1 Partnering MeetingsGeneral Session
11:30 - 11:45 Biotech Spotlight | NeOnc Technologies1:1 Partnering Meetings
11:30 - 11:45 Opening Of 1:1 Partnering MeetingsGeneral Session
11:45 - 12:00 Biotech Spotlight | Amunix1:1 Partnering Meetings
11:45 - 12:00 Opening Of 1:1 Partnering MeetingsGeneral Session
12:00 - 12:15 Biotech Spotlight | Oncoceutics1:1 Partnering Meetings
12:00 - 12:15 Opening Of 1:1 Partnering MeetingsGeneral Session
12:15 - 12:30 Biotech Spotlight | Immunomic Therapeutics, Inc.1:1 Partnering Meetings
12:15 - 12:30 Opening Of 1:1 Partnering MeetingsGeneral Session
12:30 - 13:40 Networking Luncheon1:1 Partnering Meetings
12:30 - 13:40 Opening Of 1:1 Partnering Meetings13:40 - 14:20 Panel Discussion | A Thorough and Swift Approach to Due Diligence
Speakers:
Robert Bagdorf Vice President of Worldwide Business Development Pfizer Inc.
Patrick Gallagher Vice President of Business Development Noven Pharmaceuticals, Inc.
Kathryn Gregory Executive Director, Business Development Purdue Pharma
Adam Marcus Principal DRI Capital
Younes Bekkali Director, BD&L, Strategic Transactions Boehringer Ingelheim Pharmaceuticals, Inc.
Moderator:
Ashlee Dunston Director of Healthcare Research Guidepoint
Robert Bagdorf Vice President of Worldwide Business Development Pfizer Inc.
Patrick Gallagher Vice President of Business Development Noven Pharmaceuticals, Inc.
Kathryn Gregory Executive Director, Business Development Purdue Pharma
Adam Marcus Principal DRI Capital
Younes Bekkali Director, BD&L, Strategic Transactions Boehringer Ingelheim Pharmaceuticals, Inc.
Moderator:
Ashlee Dunston Director of Healthcare Research Guidepoint
• What are the key challenges in conducting diligence?
• What do you perceive to be the key challenges?
• What approaches are most effective in getting validated insights faster?
Boehringer Ingelheim Pharmaceuticals, Inc.
• What do you perceive to be the key challenges?
• What approaches are most effective in getting validated insights faster?
Younes Bekkali
Director, BD&L, Strategic TransactionsBoehringer Ingelheim Pharmaceuticals, Inc.
General Session
14:20 - 15:00 Panel Discussion | From Disruptive to Traditional, The Latest Trends in VC Funding
Speakers:
Asish Xavier Vice President, Venture Investments Johnson & Johnson
Elaine Jones Executive Director, Venture Capital Pfizer Inc.
Leon Chen Venture Partner OrbiMed Advisors
Jeremy Bender Chief Operating Officer Tizona
Rajeev Dadoo Partner SR One
Moderator:
Anshul Thakral Senior Vice President PPD Biotech
Asish Xavier Vice President, Venture Investments Johnson & Johnson
Elaine Jones Executive Director, Venture Capital Pfizer Inc.
Leon Chen Venture Partner OrbiMed Advisors
Jeremy Bender Chief Operating Officer Tizona
Rajeev Dadoo Partner SR One
Moderator:
Anshul Thakral Senior Vice President PPD Biotech
• What are the latest developments in the emerging model of companies started by VCs?
• What is the current appetite for risk across the biopharma venture community?
• How do strategies differ from large VC to new venture funds?
• What is the current appetite for risk across the biopharma venture community?
• How do strategies differ from large VC to new venture funds?
1:1 Partnering Meetings
14:20 - 15:00 1:1 Partnering MeetingsGeneral Session
15:00 - 15:40 Networking And Refreshment Break1:1 Partnering Meetings
15:00 - 15:40 1:1 Partnering MeetingsGeneral Session
15:40 - 15:55 Biotech Spotlight | KLOX Technologies1:1 Partnering Meetings
15:40 - 15:55 1:1 Partnering MeetingsGeneral Session
15:55 - 16:10 Biotech Spotlight | Sequence Bio1:1 Partnering Meetings
15:55 - 16:10 1:1 Partnering MeetingsGeneral Session
16:10 - 16:25 Biotech Spotlight | Enable Injections1:1 Partnering Meetings
16:10 - 16:25 1:1 Partnering MeetingsGeneral Session
16:25 - 17:05 Panel Discussion | Key Strategies for Success in Early Stage Partnering
Moderator:
Scott Shaunessy CEO ideaPoint
Speakers:
Steven Bartz Director, Worldwide Licensing Merck
Michael Bayewitch Director, S&E, Biologics Teva Pharmaceuticals USA
Lisa Beck Head of Transactions, Global Business Development Alexion Pharmaceuticals, Inc
Dr. Gary VanSavage Senior Director, Transactions, Janssen Business Development Johnson & Johnson
Sylvaine Cases Senior Director, External Innovation Sanofi
Scott Shaunessy CEO ideaPoint
Speakers:
Steven Bartz Director, Worldwide Licensing Merck
Michael Bayewitch Director, S&E, Biologics Teva Pharmaceuticals USA
Lisa Beck Head of Transactions, Global Business Development Alexion Pharmaceuticals, Inc
Dr. Gary VanSavage Senior Director, Transactions, Janssen Business Development Johnson & Johnson
Sylvaine Cases Senior Director, External Innovation Sanofi
• What data are buyers looking for?
• How can you best differentiate your product in a crowded space?
• With pharma and VCs taking a greater interest in early stage opportunities, what can biotech and academic institutions do to be most competitive?
Johnson & Johnson
• How can you best differentiate your product in a crowded space?
• With pharma and VCs taking a greater interest in early stage opportunities, what can biotech and academic institutions do to be most competitive?
Dr. Gary VanSavage
Senior Director, Transactions, Janssen Business DevelopmentJohnson & Johnson